Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05389787 · ClinicalTrials.gov registry record · NA

Impact of Cerebellar TMS on Brain and Cognitive Functions in Schizophrenia: a Pilot Study

A NA study of Schizophrenia and Condition, sponsored by Northwell Health.

Recruiting
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT05389787: Recruiting NA study of Schizophrenia and Condition, sponsored by Northwell Health.

NCT05389787 is a NA study of Schizophrenia and Condition that is actively recruiting participants, run by Northwell Health. The registered enrollment target is 40 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05389787, a NA study of Schizophrenia and Condition, is actively recruiting participants, sponsored by Northwell Health.

RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

This is a single-site, sham-controlled, randomized trial in a total of 40 subjects between ages 18 and 60 years with schizophrenia. This study will investigate the effects of 4-week rTMS treatment on brain and cognitive functions in patients. Subjects will be randomized to one of the following arms: Arm 1: Standard of Care (SOC) and active rTMS Arm 2: Standard of Care (SOC) and sham rTMS Each participant will receive rTMS five days per week, for four consecutive weeks. Functional magnetic resonance imaging (fMRI) scans, clinical assessments, and cognitive tests will be performed at baseline, end of the 2nd week, and end of the 4th week.

Primary Outcome

Changes of cerebellar connectivity after TMS treatment compared with baseline, as measured by functional magnetic resonance imaging (fMRI)

Interventions

  • DEVICE Transcranial Magnetic Stimulation

Study Locations (1)

New York

  • Zucker Hillside Hospital - New York

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2022-08-18
Est. Completion 2027-08-31
Phase NA
Northwell Health

370 total trials

What NCT05389787 shows while recruiting

NCT05389787 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (82% lower).

The record links to 3 conditions, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Transcranial Magnetic Stimulation is the first listed.

NCT05389787 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT05389787 about?

NCT05389787 is a clinical study titled "Impact of Cerebellar TMS on Brain and Cognitive Functions in Schizophrenia: a Pilot Study". This is a single-site, sham-controlled, randomized trial in a total of 40 subjects between ages 18 and 60 years with schizophrenia. This study will investigate the effects of 4-week rTMS treatment on brain and cognitive functions in patients. Subjects will be randomized to one of the following arms:...

What is the current status of trial NCT05389787?

This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2022-08-18. Estimated completion is 2027-08-31.

What conditions does trial NCT05389787 study?

This clinical trial studies the following conditions: Schizophrenia, Condition, Cerebellar Function.

What interventions are being tested in trial NCT05389787?

The interventions under investigation include: Transcranial Magnetic Stimulation (DEVICE).

Who is sponsoring clinical trial NCT05389787?

This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05389787 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05389787's enrollment target sits among peer trials

40 233rd of 315 higher than 73 of 315 other Schizophrenia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05389787, the US trial registry maintained by the National Library of Medicine. NCT05389787 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.